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Abstract
Purpose of Review The field of acute myeloid leukemia (AML) has been revolutionized in recent years by the advent of high-
throughput techniques, such as next-generation sequencing. In this review, we will discuss some of the recently identified
mutations that have defined a new molecular landscape in this disease, as well as their prognostic, predictive, and therapeutic
implications.
Recent Findings Recent studies have shown howmany cases of AML evolve from a premalignant period of latency characterized
by the accumulation of several mutations and the emergence of one or multiple dominant clones. The pattern of co-occurring
mutations and cytogenetic abnormalities at diagnosis defines risk and can determine therapeutic approaches to induce remission.
Besides the genetic landscape at diagnosis, the continued presence of particular gene mutations during or after treatment carries
prognostic information that should further influence strategies to maintain remission in the long term.
Summary The recent progress made in AML research is a seminal example of how basic science can translate into improving
clinical practice. Our ability to characterize the genomic landscape of individual patients has not only improved our ability to
diagnose and prognosticate but is also bringing the promise of precision medicine to fruition in the field.
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Introduction
Acute myeloid leukemia is an aggressive and highly hetero-
geneous disease, with biologically and prognostically differ-
ent subtypes [1]. Over 40 years have passed since pioneering
work by Janet Rowley defined AML as a genetic disease with
the description of the t(15;17) as a recurrent event in acute
promyelocytic leukemia (APML) [2, 3]. Over the last few
decades, we have witnessed a growing application of several
high-throughput sequencing technologies, including whole
genome, exome, and panel-based capture sequencing, that
have helped refine the classification and prognostic scoring
of AML. Current state-of-the-art iterations of these tools, the
WHO classification (2016) and the European Leukemia Net
(ELN) guidelines, have become the “industry standards.”
Well-established poor-risk prognostic variables in AML
include older age, secondary disease, and adverse cytoge-
netics; however, recent analyses have also suggested the
value of incorporating gene mutations beyond FLT3,
NPM1, and CEBPA (e.g., IDH1and IDH2, ASXL1, MLL,
DNMT3A, and TET2) into AML risk classifications [4].
Despite the advances in our understanding of the pathogen-
esis of AML, the standard of care still remains based
around a “one size fits all” approach of age-adapted remis-
sion induction with chemotherapy and post-remission con-
solidation with chemotherapy and/or allogeneic hemato-
poietic stem cell transplant in younger patients. However,
as the mutational landscape of AML is mapped in more
detail, our therapeutic expectation in AML must evolve to
match our increasing understanding of AML pathogenesis,
with potential associated therapeutic vulnerabilities identified.
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Cytogenetics in the DNA Era
Diagnostic karyotype remains the most powerful prognostic
indicator in AML and forms the basis of current prognostic
scores. To give an example of the key role cytogenetics plays
in the diagnosis of AML, the WHO classification has
established that patients with the clonal, recurring cytogenetic
abnormalities t(8;21)(q22;q22), inv. (16)(p13q22) or
t(16;16)(p13;q22), and t(15;17)(q22;q12) should be consid-
ered to have AML regardless of the blast percentage [5]. By
dividing patients into three risk groups, favorable, intermedi-
ate, and adverse [6], cytogenetics has been widely adopted to
provide the framework for risk-adapted treatment approaches
[7]. In certain situations, cytogenetics also allow for prediction
of effective therapy; in patients with the t(15;17)(q22;q21)/
PML-RARA, for instance, the combination of all-trans retinoic
acid (ATRA) and anthracycline-based protocols has resulted
in a markedly improved outcome. In contrast patients with
complex karyotype (≥ 3 or ≥ 5 abnormalities depending on
the classification system), monosomal karyotype (such as
monosomy 5/del(5q) or monosomy 7/del(7q)), or abnormali-
ties of 3q have been shown to have inferior complete remis-
sion rates and overall survival and are currently considered for
allogeneic stem cell transplant in first remission.
However, although cytogenetic analysis remains mandato-
ry in the evaluation of suspected myeloid leukemia, it also
presents several limitations. Apart from technical failures, cy-
togenetics cannot identify cryptic rearrangements, for exam-
ple, 5% of PML/RARA positive AML lack the classic t (15,
17), with the fusion gene resulting from more complex rear-
rangements [8]. These patients not only respond to targeted
therapy in a similar fashion to patients with the classic trans-
location but also share the same favorable prognosis and re-
quirement for ATRA to prevent catastrophic coagulopathy,
therefore cannot be missed. Moreover, around 40–50% of
adult and 25% of pediatric AML patients have a normal kar-
yotype (CN-AML), and these individuals are highly heteroge-
neous in terms of clinical outcomes [11]. Therefore, improv-
ing risk stratification and clinical decision making for this
group of patients is a vibrant focus of research. In this effort,
the mutational analysis of FLT3, NPM1, and CEBPA has be-
come standard practice to improve their risk stratification [12].
There are however several additional gene mutations that also
appear to carry prognostic relevance that include IDH1, IDH2,
KIT, WT1, and RUNX1 [13], and their incorporation into risk
stratification scoring is a matter of ongoing debate.
The Molecular Landscape of AML
The advent of massive parallel sequencing heralded a new age
in molecular diagnosis, prognosis, and prediction. AML was
the first cancer genome to be sequenced [14] and remains one
of the most highly sequenced tumors, with ease of access of
tumor tissue an obvious facilitating factor. However, even
prior to this, a number of candidate gene studies had deter-
mined point and more complex mutations in critical genes,
and we will summarize these below.
The Nucleolar Protein Nucleophosmin 1
(NPM1)
Mutations in the NPM1 gene are among the most common
genetic changes in AML (occurring in 25–35% of patients),
especially in CN-AML (present in 45–64%) [15]. NPM1
plays a role in numerous cellular functions, including ribo-
some biogenesis, DNA repair, and regulation of apoptosis.
More than 40 different mutations in the C-terminal region of
the protein have been described, but these uniformly result in
the disruption of an N-terminal nucleolar localization signal
and cause the protein to be aberrantly localized to the cytosol
[16]. NPM1 mutations appear to be late driver events often
occurring after DNMT3A, IDH1, or NRAS mutations [9••].
Interestingly, however, NPM1-mutated AML behaves as an
entity on its own and is the largest classification category in a
recent 11 component classification [9••]. NPM1mutations are
not normally observed in patients with AML associated recur-
rent translocations, and murine models of NPM1mutation are
associated with expanded myelopoiesis and the development
of AML [17]. The prognostic implications of NPM1 muta-
tions in individual patients are highly dependent on the pattern
of co-occurring mutations and confer favorable prognosis on-
ly if associated with FLT3-ITD wild-type or low allelic ratio.
Growing evidence suggests that carrying an NPM1 mutation
confers sensitivity to novel agents such as venetoclax [10].
Mutations in Signaling Pathway Components
Fms-Like Tyrosine Kinase 3 (FLT3)
FLT3 is a tyrosine kinase that acts as a cytokine receptor for
the FLT3 ligand. First described in 1991, FLT3 is strongly
expressed in hematopoietic stem cells with important roles
in cell survival and proliferation [18]. FLT3 mutations are
among the most common mutations in AML and occur as
either in-frame duplications within the juxtamembrane region
(FLT3-ITD, internal tandem duplication) or as point mutations
within the tyrosine kinase domain (FLT3-TKD) at a frequency
of around 25% and 7% of AML cases, respectively [1]. Both
mutations constitutively activate the tyrosine kinase leading to
enhanced RAS, MAPK, and STAT5 signaling that results in
blast proliferation [19, 20]. The effect on prognosis is modu-
lated by the mutated to wild-type allele ratio. This may reflect
a dominant clone and/or uniparental disomy of Ch13 on
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which FLT3 resides and an increased ratio is associated with
an inferior outcome. In addition, FLT3-ITD mutations are as-
sociated with increased risk of relapse, whereas the prognostic
relevance of FLT3-TKDmutations remains controversial [21].
Recent studies have suggested that inhibitors of FLT3 are
effective as single agents in the relapsed refractory setting,
as up-front adjuvants to conventional therapy in newly diag-
nosed patients and possibly in the maintenance setting also
(RATIFY, QuANTUM-R and ADMIRAL studies).
With the ability to sequence AML genomes, it has become
apparent that a number of other genes encoding for signaling
pathways components (RAS, cKIT, NF1, and others) are mu-
tated in AML. The observation that mutations in signaling
pathways proteins frequently co-occur with chromosomal re-
arrangements in hematopoietic transcription factors (PML-
RARA, CBFβ-MYH11, RUNX1-RUNX1T1) led to the hypoth-
esis that AML results from the cooperation of mutations that
confer a proliferative advantage (class I mutations) with mu-
tations that induce a block in differentiation (class II muta-
tions), the 2-hit model [1]. However, over 40% of AML cases
lack mutations in classical signaling pathway genes, suggest-
ing that the evolution of acute leukemia is a more complex and
individual phenomenon [22].
Mutations in Epigenetic/Chromatin Modifiers
In recent years, a number of epigenetic and chromatin modi-
fiers have been identified as mutated in AML. These muta-
tions are classically found at the highest variant allele frequen-
cies (VAF) in AML patients [9••] and can also persist in re-
mission, [23] leading to the acceptance that these mutations
often represent preleukemic events [24]. In the most recent
large classification of AML, this group was also demonstrated
to have a poor prognosis, [9••] a finding recapitulated for
individual genes [25]. Efforts are therefore ongoing to dissect
this group further, as epigenetic and chromatin modifiers rep-
resent effective therapeutic targets [26].
DNA Methyltransferase 3A (DNMT3a)
DNMT3A mutations occur in 18–22% of all AML cases and
approximately 34% of CN-AML cases [27], and they are
mostly heterozygous and commonly affect a hotspot encoding
arginine at codon 882 (~ 60% of AML cases). R882mutations
appear to result in a hypomorphic protein that acts in a dom-
inant negative manner, inhibiting the methyltransferase activ-
ity of the remaining wild-type DNMT3A [28]. In murine
models, when Dnmt3a is conditionally deleted, self-renewal
is favored over differentiation [29], but the underlying mech-
anisms, and their relationship to DNA methylation, remain
unexplained. The prognostic significance of DNMT3A muta-
tions remain controversial, but recent evidence suggests that
DNMT3A-mutated AML patients may benefit from higher
doses of anthracyclines [30].
Ten–Eleven Translocation 2 (TET2)
TET2 is found mutated in about 9%–23% of AML patients
[31]. TET2 regulates the initial step in DNA demethylation
through the conversion of 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5hmC). In general, TET2 mutations
are thought to be loss-of-function mutations; however, despite
several studies, their prognostic significance remains unclear.
Additional Sex Comb-Like 1 (ASXL1)
ASXL1 loss-of-function mutations occur in ~ 5–11% of AML
cases [32]. Although their mechanisms of action are not fully
known, it is likely that they function, at least in part, through a
loss of PRC2 (polycomb repressive complex 2) function
allowing derepression of genes such as HOXA cluster genes
[33]. ASXL1 mutations are five times more common in older
(> 60 years) patients, are frequently associated with t(8;21),
wild-type NPM1, wild-type FLT3, and mutated CEBPA, and
are considered adverse prognostic factors according to
European Leukemia Net (ELN) criteria.
Isocitrate Dehydrogenase (IDH)
IDH 1 and 2 gene mutations are neomorphic gain-of-function
mutations that cause an alteration of normal function,
allowing the mutant enzyme the novel function of further
converting α-ketoglutarate into 2-hydroxyglutarate (2-HG).
This “oncometabolite” inhibits the function of TET2 and other
dioxygenase enzymes causing effects on DNA and histone
methylation and thus epigenetic regulation [34]. IDH1 muta-
tions more commonly affect the highly conserved arginine (R)
residue at codon 132 (R132) and have been identified in 7% of
AML patients. IDH2 mutations are identified in a further 9%
of cases and cluster at codons R140 and R172 [1].
Interestingly IDH2 mutations are prognostically distinct,
whereas R140 mutations are often associated with NPM1
and predict more favorable outcomes, and R172 mutations
seem to represent a distinct genomic subgroup with mutual
exclusivity with NPM1 and indicate poorer prognosis [9••].
Cohesin Complex
Cohesin is a large ring-shaped multi-protein complex
consisting of four major subunits: SMC1A, SMC3, RAD21,
and STAG1/2. Cohesin plays a role not only in mediating
sister chromatid cohesion during mitosis, where it coordinates
ordered chromosome separation and prevents mitotic catastro-
phe, but is also involved in DNA damage repair and the
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regulation of gene expression through coordinating interaction
between distal and proximal cis-regulatory elements.
Mutations in Cohesin subunits affect around 10% of AML
patient [35] and typically co-occur with NPM1, DNMT3A,
TET2, or RUNX1 mutations [36]. Cohesin mutations or
knockdown of Cohesin subunits impair hematopoietic differ-
entiation and enforce stem cell programs in both human and
mouse hematopoiesis. Furthermore, studies have demonstrat-
ed alterations of chromatin accessibility upon depletion of
Cohesin function and have further linked AML development
with a requirement of Cohesin function for dynamic gene
expression during erythroid differentiation and interaction
with ETS transcription factors [37, 38].
RNA Splicing Factor Mutations
A number of RNA splicing factors are mutated in AML. The
most commonly mutated genes include SF3B1, U2AF1,
SRSF2, and ZRSR2 [39]. Often considered founding events,
splicing factor gene mutations are frequently found in
preleukemic conditions such as MDS. In newly diagnosed
AML patients, spliceosome gene mutations are now consid-
ered pathognomonic of secondary AML developing from pre-
ceding MDS [40]. These mutations are likely to alter splicing
and subsequent translation of critical genes and are generally
associated with poorer responses.
Transcription Factor Mutations
Runt-Related Transcription Factor (RUNX1)
The RUNX1 gene is a partner in the t(8;21) fusion gene in
CBF leukemia and is also affected by recurrent gene muta-
tions in AML [41]. RUNX1 mutations are found in 5–13% of
AML cases and are commonly associated with trisomy 13,
trisomy 21, absence of NPM1, and CN-AML [42]. In sharp
contrast with the favorable prognostic effect of gene fusions
involving RUNX1, RUNX1 mutations are associated with re-
sistance to standard induction therapy and with inferior overall
survival, for both younger and older patients, and are an ad-
verse risk factor in the 2017 ELN guidelines [43].
CCAAT Enhancer Binding Protein α (CEBPA)
CEBPA is a transcription factor that plays a key role in hema-
topoiesis and is a master regulator of myeloid differentiation
[44]. Mutations occur in 6 to 10% of AML cases [45] and are
identified in both amino and carboxy-terminal regions, with
the latter resulting in a truncated protein that is unable to
dimerize and bind DNA [46]. Only bi-allelic, not single,
CEBPA mutations predict an increased CR rate and favorable
survival. CEBPA mutations can also be inherited through the
germline, with this subset of patients often going on to devel-
op AML with the acquisition of additional mutations that in-
clude but are not exclusive to the other CEBPA allele [47].
Tumor Suppressor Gene Mutations
TP53
Mutations in the tumor suppressor TP53 are identified in 8% of
AML cases and are associated with complex karyotype, therapy-
related AML, chemo-resistance, high relapse rate, and poor sur-
vival [48]. These mutations also confer an adverse risk in the
European LeukemiaNet (ELN) guidelines and patients that carry
a TP53 mutation are poorly served by current therapeutic
strategies.
The Evolution of AML from a Latent
Preleukemic State
More recently, AML-associated mutations have been found in
healthy aging individuals, a condition named age-related clonal
hematopoiesis (ARCH) or clonal hematopoiesis of indeterminate
potential (CHIP), and its incidence is as high as 10% in individ-
uals over 65 years of age. These individuals have a higher risk of
hematological malignancies and cardiovascular disease [49, 50].
The acknowledgment that AML has a period of latent
preleukemia of at least several years in many cases has been a
major step forward in understanding the evolution and kinetics of
this aggressive disease. Most cases of ARCH involve mutations
in epigenetic regulators such as DNMT3A, ASXL1, and TET2,
whereas FLT3 and NPM1 mutations are never observed, sug-
gesting that these are later cooperating events. Interestingly, de-
spite the fact that ARCH is very prevalent in the general aging
population, AML remains a rare disease (~ 4 cases per 100,000
individuals) [51]. Currently, the rate of transformation of ARCH
into AML is predicted to be between 0.5 and 1% per year [52].
Deep sequencing of historical samples of patients that have gone
on to developAMLhas suggested thatmutations inTP53, IDH1,
and 2 andRNA splicing factors (SRSF2, SF3B1, andU2AF1) are
associated with the highest odds of transformation. In these large
cohort studies, DNMT3A and TET2mutations appeared as com-
monly occurring events in both AML and control cases, but
higher VAFs (> 10%), the presence of a higher number of vari-
ants (two or more), along with clonal complexity, correlated with
a greater risk of AML [53•, 54•].
The recent identification of a true preleukemic state has
changed our view on AML and has identified the possibility of
a new treatment paradigm; prevention of the evolution of this
deadly disease during its latent phase, with much research, cur-
rently devoted to this. The highest risk individuals seem to be
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those with a detectable TP53 clone [54•], but at the moment,
there are no established strategies to eliminate such clones.
IDH and splicing factor mutant clones have potential therapeu-
tics; however, these treatments are not without toxicity, and a
greater predictive capacity, less toxic therapies, and careful clin-
ical trials are needed to justify widespread preemptive
intervention.
Prognostic and Therapeutic Implications
of Defining the Molecular Landscape of AML
in Individual Patients
The most immediate consequence of the next-generation se-
quencing revolution has been to improve the risk stratification
of AML patients. Indeed, in 2017 the European Leukemia
Network recognized the prognostic value of some of the mu-
tations discussed above and updated their risk stratification
criteria (Table 1) [55].
Several studies continue to suggest that incorporating a
broader list of gene mutations than indicated by ELN 2017
could further refine risk stratification, but more importantly, it
is becoming clear that the prognostic effect of a given muta-
tion depends on the pattern of co-occurring mutations. For
instance, Papaemmanuil et al. described how the negative ef-
fect of aFLT3 ITD in patients with anNPM1mutation ismuch
more pronounced when DNMT3A is also mutated. Likewise,
in patients with an NPM1 mutation, the presence of a RAS
mutation improved survival more in the presence than in the
absence of a DNMT3A mutation. Analogously, the adverse
effect of an MLL aberration noted in European Leukemia
Net (ELN) 2017 depended on the presence of FLT3 TKD
mutations, and although European Leukemia Net (ELN)
2017 regarded mutations in IDH2 or in DNMT3A as having
no prognostic effect, prognosis became considerably worse
when both IDH2 and DNMT3A mutations co-occurred in a
large series of patients [9••]. However, to take full prognostic
advantage of the genetic complexity in AML, where there are
usually thought to be between 3 and 5 driver mutations per
patient, will require large patient numbers and international
collaboration as is planned by large consortia such as the
HARMONY alliance (https://www.harmony-alliance.eu).
In addition to the presence of genetic abnormalities at diagno-
sis, the continued presence of particular genemutations during or
after treatment carries prognostic information for certain geneti-
cally defined AML subtypes. In NPM1-mutated AML, for in-
stance, detection of mutant NPM1 transcripts by sensitive quan-
titative RT-PCR after 2 cycles of chemotherapy had an 86%
cumulative incidence of relapse vs 34% for NPM1 negative pa-
tients [56•]. Minimal residual disease (MRD) detection, either by
genetics or by multiparameter flow cytometry (MPFC), has
therefore assumed a role in risk-adapting post-remission therapy,
which had previously been based solely on pretreatment vari-
ables. Interest hasmore recently turned to establishing if a variety
of mutations identified through NGS are persistent after treat-
ment and the potential prognostic implications. It is becoming
apparent that while detection of ARCH mutations (DNMT3A,
TET2, ASXL1) has no prognostic implication and simply
Table 1 2017 ELN risk
stratification by genetics Risk category Genetic abnormality
Favorable t(8;21)(q22;q22.1); RUNX1-RUNX1T1
inv. (16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow
Bi-allelic-mutated CEBPA
Intermediate Mutated NPM1 and FLT3-ITDhigh
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow (without adverse
risk genetic lesions)
t(9;11)(p21.3;q23.3); MLLT3-KMT2A
Cytogenetic abnormalities not classified as favorable or adverse
Adverse t(6;9)(p23;q34.1); DEK-NUP214
t(v;11q23.3); KMT2A rearranged
t(9;22)(q34.1;q11.2); BCR-ABL1
inv. (3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) -5
or del(5q); −7;
−17/abn(17p)
Complex karyotype, monosomal karyotype
Wild-type NPM1 and FLT3-ITDhigh
Mutated RUNX1
Mutated ASXL1
Mutated TP53
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underlies the advantage of these clones over wild type in
repopulating the marrow after chemotherapy, persistence of
non-ARCH mutations is associated with higher cumulative inci-
dence of relapse and shorter survival and relapse-free survival
[57], albeit that the resolution of NGS (10-2-10-3) is more limited
than either MPFC or PCR.
Finally, the research-based advances described above are
translating into clinical practice leading to a very much overdue
update in the treatment strategies available to combat AML, and
as a result, within the last 2 years, the US Food and Drug
Administration (FDA) approved eight novel therapies for pa-
tients with AML, many of which are also becoming available
in Europe (Fig. 1). Midostaurin, a FLT3 inhibitor, was one of the
first novel therapies to enter clinical practice and is currently
recommended in combinationwith chemotherapy and as a single
agent for maintenance therapy in patients with mutated FLT3
[58]. Similarly, the IDH1 and IDH2 inhibitors ivosidenib and
enasidenib have shown promising results in clinical trials and
have been approved for use in AML patients with IDH1 and
IDH2mutations, respectively [59, 60]. To further champion per-
sonalized medicine in AML, the Leukemia and Lymphoma
Society is sponsoring a “BEAT AML” trial that plans to recruit
500 patients aged 60 or above with newly diagnosed AML. The
trial aims firstly to assess the feasibility of enrolling patients
based on mutational status. Following a genomic screening
whose results should be available within 7 days of a marrow
sample being taken, patients will be assigned to one of several
arms based on their genetic profile. The results of this and other
similar trials proposed or in set up are eagerly awaited as they
will not only pave the way towards the use of precision medicine
in AML but also will begin to test the efficacy of several novel
targeting agents in a cohort of newly diagnosed older patients,
who are the patient group with the highest mortality rates and
lowest tolerance for toxic therapies.
Conclusions
The advent of rapid and affordable genome sequencing has
revolutionized our approach to the classification, prediction,
and prognostication of acute myeloid leukemia and has great-
ly improved our scientific understanding of the pathophysiol-
ogy of this deadly disease. This has initially translated into an
improved ability to determine which patients will benefit most
from allogeneic stem cell transplantation in first remission, but
now, thanks to a growing therapeutic armamentarium, is at
last leading to a long overdue clinical progress in AML ther-
apy and to the promise of individualized approaches to im-
prove outcomes in this deadly disease.
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Fig. 1 Timing of the identification of mutations associated with AML
and evolution of therapeutic strategies. More widespread use of
sequencing technologies has enriched the landscape of mutations that
are associated with AML. An enhanced ability to diagnose and
prognosticate is now translating into an increased understanding of
therapeutic vulnerabilities and the development of new therapies.
Between 2017 and 2018, the FDA has approved eight novel drugs for
the treatment of AML and for the first time in almost 40 years, and AML
patients can benefit from a more individualized treatment approach
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